Abstract Body

The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson’s disease (PD) progression. During the past ten years, the PPMI study has established a robust clinical and biomarker dataset. PPMI has now expanded to increase the number of participants across the PD continuum from prodromal to moderate PD and identify and explore the use of biomarkers to test hypotheses of the underlying molecular pathobiology of PD, enable modeling of PD progression to identify clinical and/or biologic data driven PD progression sub-sets, and inform studies testing PD therapeutics.

The expanded PPMI will will include the current PPMI cohorts plus approximately 1000 early PD and healthy participants and 2000 participants with Prodromal PD. The prodromal cohort will be enrolled based on a staged risk paradigm with initial assessment via PPMI online followed by DAT imaging to determine eligibility to participate in a five-year densely phenotypes longitudinal study.

We will present examples of PPMI data on that demonstrates the staged risk paradigm for prodromal PD and will provide exploratory data identifying clinical subsets of PD that may predict disease progression. PPMI will expand the existing data set and biorepository already available from PPMI. The PPMI expansion has the potential to establish a framework for developing a prodromal PD cohort and to identify meaningful clinical and biomarker outcomes that could accelerate clinical trials of both manifest and prodromal PD.